Chembio Diagnostics Provides Update on Regulatory Status of DPP HIV-Syphilis System
MEDFORD, N.Y., March 03, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, is providing an update on the FDA Premarket Approval (PMA) application for Chembio’s DPP …